<DOC>
	<DOCNO>NCT03082885</DOCNO>
	<brief_summary>A randomize control trial evaluate efficacy safety Thymosin-α1 administration patient HBV-related Acute-on-chronic liver failure .</brief_summary>
	<brief_title>The Efficacy Safety Thymosin-α1 Patients With HBV-related ACLF .</brief_title>
	<detailed_description>Hepatitis B virus ( HBV ) -related acute-on-chronic liver failure ( ACLF ) severe disease high mortality . In study , intend assess efficacy safety Thymosin-α1 patient HBV-related Acute-on-chronic liver failure .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<criteria>1.Chronic hepatitis B . 2.defined acute deterioration Transaminase great equal 10 NUT time over14 day . 3.development jaundice ( serum bilirubin great equal 5mg/dl ) . one criteria： 4.development coagulopathy ( INR≥1.5 ) . 5.development hepatic encephalopathy . 6.development renal insufficiency ( serum creatinine ≥ 2 mg/dl ) . 7.Hepatic narrowing . 8.development massive ascites peritonitis . 1.Patients hepatocellular carcinoma . 2.Patients autoimmune disease . 3.Patients significant comorbid illnesses cardiovascular respiratory intrinsic renal disease may bear outcome . 4.Patients disseminate intravascular coagulation . 5.Drug allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>